Recombinant human interleukin 4 (rhuIL-4) is a candidate for the treatment of refractory cancer based on its potential to enhance immune function. Recombinant human IL-4 was administered subcutaneously at 0, 1, 5, or 25 μg/kg/day for 28 days with a 14-day recovery to male and female cynomolgus monkeys as part of the preclinical safety evaluation. Clinical pathologic changes related to treatment with rhuIL-4 were evidence of consumptive coagulopathy, erythrocyte fragmentation, lymphocytosis, and lymphocyte morphologic changes indicative of marked antigenic or mitogenic stimulation, mild eosinophilia and neutrophilia, hypoalbuminemia, hypocholesterolemia, and hypertriglyceridemia. Based on data obtained after the 14-day recovery period, the clinical pathologic changes associated with rhuIL-4 administration were considered to be reversible.
1. Anderson TD and Hayes TJ (1989). Toxicity of human recombinant interleukin-2 in rats. Lab. Invest60: 331–346.
2.
2. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi T-A, Decker K, and Heinrich PC (1988). Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur. J. Biochem173: 287–293.
3.
3. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, and Yokota T (1990). Cytokines: Coordinators of immune and inflammatory responses. Annu. Rev. Bio chem59: 783–836.
4.
4. Argiles JM, Lopez-Soriano FJ, Evans RD, and Williamson DH (1989). Interleukin-1 and lipid metabolism in the rat. Biochem. J259: 673–678.
5.
5. Barbolt TA, Gossett KA, and Cornacoff JB (1991). Histomorphologic observations for cynomolgus monkeys after subchronic subcutaneous injection of recombinant human interleukin-4. Toxicol. Pathol19: 251–257.
6.
6. Beutler B and Cerami A (1988). An endogenous mediator of cellular catabolism and shock. Adv. Inflam. Res12: 23–32.
7.
7. Broxmeyer HE, Lu L, Cooper S, Tushinski R, Mochizuki D, Rubin BY, Gillis S, and Williams DE (1988). Synergistic effects of purified recombinant human and murine B cell growth factor/IL-4 on colony formation in vitro by hematopoietic progenitor cells. Multiple actions. J. Immunol141: 3852–3862.
8.
8. Castel JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, and Heinrich PC (1988). Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett232: 347–350.
9.
9. Evans RD, Argiles JM, and Williamson DH (1989). Metabolic effects of tumour necrosis factor-α (cachectin) and interleukin-1. Clin. Sci77: 357–364.
10.
10. Hart PH, Burgess DR, Vitti GF, and Hamilton JA (1989). Interluekin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood74: 1222–1225.
11.
11. Ishizaka A, Joh K, Shibata R, Wagatsuma U, Nakanishi M, Tomizawa K, Kojima K, Kandil E, Sakiyama Y, and Matsumoto S (1990). Regulation of IgE and IgG4 synthesis in patients iwth hyper IgE syndrome. Immunology70: 414–416.
12.
12. Le J and Vilcek J (1987). Tissue necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab. Invest56: 234–248.
13.
13. Le J and Vilcek J (1989). Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest61: 588–602.
14.
14. London L and McKearn JP (1990). The dual regulatory role of interleukin 4 is mediated through a direct effect on the target cell. Exp. Hematol18: 1059–1063.
15.
15. Marder VJ (1983). Consumptive thrombohemorrhagic disorders. In: Hematology, WJ Williams, E Beutler, AJ Erslev, and MA Lichtman (eds). McGraw-Hill, New York, pp. 1433–1461.
16.
16. Migliaccio AR and Migliaccio G (1990). The control of proliferation and differentiation of early erythroid progenitors. Biotherapy2: 299–303.
17.
17. O'Garra A, Umland S, De France T, and Christiansen J (1988). B-cell factors are pleotropic. Immunol. Today9: 45–54.
18.
18. Peschel C, Paul WE, Ohara J, and Green I (1987). Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood70: 254–263.
19.
19. Prinz JC, Baur X, Mazur G, and Rieber EP (1990). Allergen-directed expression of Fc receptors for IgE (CD23) on human T lymphocytes is modulated by interleukin 4 and interferon-γ. Eur. J. Immunol20: 1259–1264.
20.
20. Rennick D, Yang G, Muller-Sieburg C, Smith C, Arai N, Takabe Y, and Gemmell L (1987). Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA84: 6889–6893.
21.
21. Rosenzweig IB, Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E, Shrago ES, and Sondel PM (1990). Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy2: 193–198.
22.
22. Sato T, Misago M, Tsukada J, Kikuchi M, Oda S, Chiba S, and Eto S (1990). Effect of interleukin-4 on the growth of granulocyte-macrophage progenitor cells stimulated by hematopoietic growth factors. J. UOEH12: 163–174.
23.
23. Sokal RR and Rohlf FJ (1981). Biometry, 2nd ed. W. H. Freeman, New York.
24.
24. Street NE and Mosmann TR (1990). IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactions. Biotherapy2: 347–362.
25.
25. Szabo G and Miller-Graziano CL (1990). Induction and regulation of monocyte procoagulant activity. Transplantation50: 301–309.
26.
26. Tepper RI, Levinson DA, Stanger BZ, Campos-Torres J, Abbas AK, and Leder P (1990). IL-4 induces allergic-like inflammatory disease and alter T cell development in transgenic mice. Cell62: 457–467.
27.
27. Tepper RI, Pattengale PK, and Leder P (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell57: 503–512.
28.
28. Tocco-Bradley R, Georgieff M, Jones CT, Moldawer LL, Dinarello CA, Blackburn GL, and Bistrian BR (1987). Changes in energy expenditure and fat metabolism in rats infused with interleukin-1. Eur. J. Clin. Invest17: 504–510.
29.
29. Vellenga E, Wolf JTM de, Beentjes JAM, Esselink MT, Smit JW, and Halie MR (1990). Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3 supported myeloid colony formation from normal and leukemic bone marrow cells. Blood75: 633–637.
30.
30. Vercelli D, Jabara HH, Lee B-W, Woodland N, Geha RS, and Leung DYM (1988). Human recombinant interleukin 4 induces FceR2/CD23 on normal human monocytes. J. Exp. Med167: 1406–1416.
